Abzena is a leading partner research organization that offers integrated discovery, development and cGMP manufacture services for biologics and bioconjugates. Abzena provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and bioconjugation drug development and manufacturing in the biopharmaceutical industry. The company maintains resources around the world, with facilities in the US and UK. Abzena investors include Welsh, Carson, Anderson & Stowe (www.wcas.com), one of the world's leading private equity investors, and Biospring Partners (www.biospring.com/).